Muscle is remarkable. It repairs itself constantly, responding to the demands we place on it every day. In Duchenne muscular dystrophy, that repair process breaks down, and muscles can't keep up with the damage. Satellos is working to change that, with a therapy designed to reset the muscle’s own ability to rebuild. Learn how at satellos.com/science #MuscleRegeneration #Duchenne $MSLE $MSCL.TO

Great discussions underway at the @Oppenheimer CNS & Neuro-Muscular Summit. Proud to have our CEO, Frank Gleeson, join fellow industry leaders to discuss next-generation therapeutics in genetic muscle disorders. #OppenheimerSummit #NeuromuscularDisease #Duchenne $MSLE $MSCL.TO

We’re heading to @CureDuchenne FUTURES 2026 in Orlando.💙 Satellos will be presenting and exhibiting at this year’s conference, and we’re looking forward to connecting with the #Duchenne community, partners, and advocates driving progress forward. If you’re attending, stop by our booth — we’d love to meet you. #FUTURES2026 #MuscleRegeneration $MSLE $MSCL.TO

Satellos reported today its first quarter financial results and recent company progress. Full details here: ir.satellos.com/news/news-de… $MSLE $MSCL

At Satellos, we’re often focused on what’s right in front of us, including data, timelines, and next steps. At the Team Joseph #StrongerTogether meeting in Detroit, we took a moment to look further ahead. One of the sessions asked us to imagine a newspaper front page 10 years from now, capturing the big stories we hope to see for those living with #Duchenne muscular dystrophy. It was a simple exercise, but a meaningful one that connected today’s work to what it could ultimately mean. Sharing a few moments from the meeting here, including that activity, and yes, that artwork is ours. Thank you to Team Joseph for bringing the community together in such a thoughtful and impactful way. $MSLE $MSCL

Duchenne is typically viewed through the lens of muscle damage. An equally important question is: What happens to the body’s ability to repair that damage? This video outlines the biological framework behind our approach. #MuscleRegeneration #Duchenne $MSLE $MSCL

$MSLE News: Today we announced interim clinical and biomarker data for SAT-3247 at the @MDAorg Clinical & Scientific Conference in Orlando, Florida. Full details in our press release: tinyurl.com/3yybs7r9 #MDAConference #MDA2026 #MuscleRegeneration #Duchenne $MSCL

Satellos is looking forward to the 2026 @MDAorg Clinical & Scientific Conference in Orlando, March 8–11. We’ll be sharing updates on SAT-3247 and our ongoing work to advance muscle regeneration for people living with degenerative muscle diseases. Full details here: tinyurl.com/3whuv96w #MDA2026 #Duchenne #MuscleRegeneration $MSLE $MSCL

Join Satellos and Kevin M. Flanigan, MD, Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine, for a discussion on the unmet need and evolving treatment landscape in #Duchenne muscular dystrophy. The event will include an overview of SAT-3247 and updates from the completed Phase 1 program, and the TRAILHEAD and BASECAMP Phase 2 studies. More details here: tinyurl.com/2mzwa7b8 📅 February 24, 2026 ⏰ 3:30 p.m. ET 💻 Virtual 🔗 Register: lifescievents.com/event/ld1k… $MSLE $MSCL

@SatellosBio announces dosing of the first participant in the Phase 2 trial of SAT-3247, an investigational therapy being studied as a novel treatment to regenerate skeletal muscle for individuals with Duchenne. Read the press release to learn more: ir.satellos.com/news/news-de…

Satellos announced today that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for #Duchenne muscular dystrophy. Full details here: tinyurl.com/569d37xm #MuscleRegeneration $MSCL $MSLE

Satellos will be participating in a fireside chat at the @GuggSecurities Emerging Outlook: Biotech Summit 2026 in NYC on Feb. 12 at 10 a.m. ET. We look forward to sharing our recent progress and the momentum behind SAT-3247, our investigational therapy for people living with #Duchenne muscular dystrophy. Full details here: ir.satellos.com/news/news-de… $MSLE $MSCL #MuscleRegeneration

Satellos announced today that its common shares have been approved for listing on the Nasdaq Stock Market LLC and have commenced trading under the ticker “MSLE.” The Company’s common shares continue to trade on TSX under “MSCL.” More here: tinyurl.com/5brx8yuw $MSLE $MSCL #MuscleRegeneration

Happy to welcome Antoinette to Satellos as our new CDO and Head of Regulatory Affairs. Her experience strengthens our leadership team as we stay focused on execution and continue scaling the business.

Turning real biology into real progress. That’s what today looks like at Satellos. → Explore our science: satellos.com/science #MuscleRegeneration $MSCL $MSCLF

I know many families across the world who are eagerly trying to get their child into the Phase II Satellos clinical trial. There’s great energy and a lot of hope right now! I love it so much!

Satellos is heading to San Francisco for the @jpmorgan Healthcare Conference next week. With BASECAMP, our Phase 2 trial of SAT-3247 in children with #Duchenne, now underway, we look forward to connecting with industry leaders and the investment community to discuss the year ahead. #JPM2026 #MuscleRegeneration $MSCL $MSCLF

Looking back on a meaningful year and ahead to what’s next. #MuscleRegeneration #Duchenne $MSCL $MSCLF 🔗satellos.com

The reason behind the research. #MuscleRegeneration #Duchenne $MSCL $MSCLF Learn more at satellos.com

Today, HHS announced that #Duchenne muscular dystrophy has been added to the recommended newborn screening panel. This is an important step toward helping families get answers earlier and begin care sooner. Read more: hhs.gov/press-room/secretary…